The role of laboratory tests in Crohn's disease

M Cappello, GC Morreale - Clinical Medicine Insights …, 2016 - journals.sagepub.com
In the past, laboratory tests were considered of limited value in Crohn's disease (CD). In the
era of biologics, laboratory tests have become essential to evaluate the inflammatory burden …

[HTML][HTML] Therapeutic drug monitoring in inflammatory bowel disease

U Kopylov, S Ben-Horin, E Seidman - Annals of Gastroenterology …, 2014 - ncbi.nlm.nih.gov
Tumor necrosis factor (TNF)-α inhibitors and thiopurines are among the most important
classes of medications utilized in the clinical management of Crohn's disease and ulcerative …

[HTML][HTML] New trends in inflammatory bowel disease

C Palmela, J Torres, M Cravo - GE Portuguese journal of gastroenterology, 2015 - Elsevier
Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the
gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has …

[HTML][HTML] Serum infliximab cutoff trough level values for maintaining hematological remission in pediatric inflammatory bowel disease

SY Choi, B Kang, YH Choe - Gut and Liver, 2019 - ncbi.nlm.nih.gov
Methods Patients with pediatric IBD who had received IFX infusions between December
2008 and March 2015 at Samsung Medical Center were retrospectively investigated. We …

A nationwide survey on therapeutic drug monitoring of anti‐tumour necrosis factor agents for inflammatory bowel disease

PWA Thomas, PKL Chin… - Internal medicine journal, 2021 - Wiley Online Library
Background Routine therapeutic drug monitoring (TDM) during treatment with anti‐tumour
necrosis factor (anti‐TNF) agents in inflammatory bowel disease may increase treatment …

Laboratory Tests in Crohn's Disease

GC Morreale, M Cappello, A Craxì - Crohn's Disease: Radiological …, 2016 - Springer
Laboratory tests are useful for diagnosing Crohn's disease, assessing disease activity,
identifying complications, and monitoring response to therapy. Their role has been …

[HTML][HTML] Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting

WJ Sandborn, PJ Rutgeerts - gastroenterologyandhepatology.net
In an oral presentation at Digestive Disease Week 2014, Paul J. Rutgeerts, MD, PhD,
presented an overview of therapeutic drug monitoring in patients with inflammatory bowel …

[PDF][PDF] Prise en charge des poussées sévères au cours des maladies inflammatoires chroniques intestinales

MA Al Jazzar - 2016 - wd.fmpm.uca.ma
Tous les mots du monde ne sauraient exprimer l'immense amour que je porte pour vous, ni
la profonde gratitude que je vous témoigne pour tous les efforts et les sacrifices que vous …

Seguimiento de los pacientes con enfermedad inflamatoria intestinal: novedades presentadas en la Digestive Disease Week 2014

S García-López - Gastroenterología y Hepatología, 2014 - Elsevier
Acerca de la monitorización de los pacientes con enfermedad inflamatoria intestinal, en la
pasada Digestive Disease Week 2014 se han presentado muchos datos, con mayor o …

[PDF][PDF] Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Commentary

WJ Sandborn - Highlights in Anti-Tumor Necrosis Factor Monitoring …, 2014 - ncbi.nlm.nih.gov
SPECIAL MEETING REVIEW EDITION more effective for IBD patients than either drug alone.
21 Thiopurines are metabolized to the active moiety, 6-thioguanine nucleotide (6TGN), and …